FDA Accepts Supplement Application for STELARA by Janssen Biotech
The FDA has accepted the supplemental biologics application (BLA761044) for STELARA, indicating a potential expansion of its use.
Therapeutic Area
Therapeutic area intelligence for 23 Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.